KRAS and colorectal carcinoma: In CodeBreaK100, a phase I trial of 129 patients with KRAS G12C-mutated solid tumors treated with KRAS G12C inhibitor sotorasib, of the 42 patients with CRC only 3 patients (7.1%) had a disease response [65].